Novo Nordisk Readies for Pipeline Showcase as EU Clears Wegovy Pill and High-Dose Pen
Published on 05/28/2026 at 07:33 | Redaktion boerse-global.de
The Danish pharmaceutical giant enters a pivotal moment. Two regulatory approvals in Europe pave the way for a broader Wegovy franchise, while the American Diabetes Association conference looms as a potential catalyst for the company's most-watched pipeline candidate, CagriSema. Meanwhile, a massive share buyback programme continues to soak up stock, yet the shares remain deeply wounded from a year-long slide.
Novo Nordisk is spending big on its own stock. Between 18 and 22 May alone, the company snapped up 1.05 million B-shares. Since February, it has repurchased 17 million shares for around 4.47 billion Danish kroner (roughly €600 million), part of a total buyback plan worth €2 billion. The programme serves both capital reduction and the hedging of equity-based compensation plans. At €38.40, the stock still trades 45% below its 52-week high of €70.13 and has shed about 14% since the start of the year.
EU Green Light for Oral Wegovy and High-Dose Pen
The more immediate catalyst comes from the European Medicines Agency’s Committee for Medicinal Products for Human Use, which issued a positive opinion for two new Wegovy variants. The first is an oral tablet containing 25 mg of semaglutide — a potential first-in-class GLP-1 pill for weight management in the European Union. The recommendation draws on data from the SELECT study, which showed Wegovy cuts the risk of major cardiovascular events. Importantly, the oral formulation carries no restrictions on drug-drug interactions.
Demand in the United States already validates the concept. More than one million Americans used the pill in the first four months post-launch. In the first quarter of 2026, Novo Nordisk recorded 1.3 million prescriptions, with cumulative prescriptions exceeding two million. Quarterly sales of oral Wegovy reached €308 million.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The second CHMP endorsement covers a 7.2 mg single-dose pen of Wegovy, simplifying the regimen for patients who previously had to administer three separate 2.4 mg injections. The pen is already available in the US and UK. Data from the STEP-UP study showed an average weight loss of 20.7% in obese participants, with roughly one in three losing at least 25%. Among those with type 2 diabetes, the figure came in at 14.1%.
The EU Commission is expected to rubber-stamp both recommendations, allowing Novo Nordisk to launch oral Wegovy in selected non-US markets in the second half of 2026 and the high-dose pen in the EU in the third quarter.
CagriSema Takes Centre Stage in New Orleans
But the scientific community — and investors — have their eyes on New Orleans. From 5 to 8 June, the American Diabetes Association convenes its annual meeting, and Novo Nordisk will present 40 abstracts, including phase 3 results for CagriSema, the fixed-dose combination of the amylin analogue cagrilintide and semaglutide.
The REIMAGINE trial series is the headline act. In REIMAGINE 2, CagriSema produced a 1.91 percentage point reduction in HbA1c after 68 weeks and a weight loss of 14.2%. Some 43% of participants shed at least 15% of their body weight. The company filed CagriSema with the FDA in December 2025 and expects a decision by the end of 2026. The ADA data arrive at a critical moment, just before the regulator’s verdict.
Novo Nordisk will also unveil phase 2 data for Zenagamtide — formerly known as Amycretin — a once-weekly GLP-1 and amylin receptor agonist being tested for both obesity and type 2 diabetes, in oral and subcutaneous forms. Additional updates on Ozempic and Wegovy round out the presentation. A dedicated investor event on 7 June will be livestreamed.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Challenging Year Beneath the Surface
For all the pipeline optimism, the financial reality is sobering. Revenue and operating profit are expected to fall by 5% to 13% in 2026, hit by lower realised prices, reduced Medicaid reimbursement for obesity therapies, and the Most-Favored-Nations pricing agreement in the United States. The patent expiry for semaglutide in several international markets adds another layer of pressure.
The stock has recovered about 9% above its 50-day moving average and bounced from a March low of €30.48, but on a 12-month basis it is still down 37%. With the ADA conference serving as the next major inflection point, positive CagriSema data could shift expectations for the second half of the year — exactly as the FDA prepares to rule on the drug’s fate.
Ad
Novo Nordisk Stock: New Analysis - 28 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
